Press Releases

– Successful Completion of Animal Drug Interaction Studies Triggers Funding for Phase 1b Clinical Trial in Patients with CUD – SEATTLE --(BUSINESS WIRE)--Mar. 13, 2025-- Omeros Corporation (Nasdaq: OMER) today announced that it has received a funding commitment from the National Institute on Drug

– Results Demonstrate Marked Survival Superiority of Narsoplimab-Treated EAP Patients, in Stand-Alone and Combined Analyses with Narsoplimab Pivotal Trial Patients, over External Control Patients – Results of statistical analyses of survival in narsoplimab-treated expanded access program (EAP)

SEATTLE --(BUSINESS WIRE)--Feb. 14, 2025-- Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation

SEATTLE --(BUSINESS WIRE)--Feb. 10, 2025-- Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for

  – Newly Completed Sensitivity Analyses Demonstrate Robustness of Previously Announced Survival Superiority Over External Control in Patients with TA-TMA – Sensitivity analyses support the results of the primary endpoint analysis, with representative sensitivity analyses demonstrating: